Selected article for: "acute worsening and additional treatment"

Author: Thu, Phuong Nguyen Thi; Huong, Minh Ngo Thị; Thi, Ngan Tran; Thanh, Hoi Nguyen; Minh, Khue Pham
Title: Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial
  • Cord-id: c2g86b14
  • Document date: 2021_9_29
  • ID: c2g86b14
    Snippet: BACKGROUND: The role of antibiotics in the treatment of chronic obstructive pulmonary disease (COPD) exacerbations and their effectiveness in combination have not been clearly established. To determine whether using a combination of fluoroquinolones and beta-lactams improves the clinical and microbiological efficacy of antibiotics on day 20 of treatment, we conducted an open-label randomized trial based on clinical outcomes, microbiological clearance, spirometry tests, and signs of systemic infl
    Document: BACKGROUND: The role of antibiotics in the treatment of chronic obstructive pulmonary disease (COPD) exacerbations and their effectiveness in combination have not been clearly established. To determine whether using a combination of fluoroquinolones and beta-lactams improves the clinical and microbiological efficacy of antibiotics on day 20 of treatment, we conducted an open-label randomized trial based on clinical outcomes, microbiological clearance, spirometry tests, and signs of systemic inflammation in patients hospitalized with acute exacerbations of COPD. METHODS: We enrolled 139 subjects with COPD exacerbations, defined as acute worsening of respiratory symptoms leading to additional treatment. Patients were divided randomly into two groups: 79 patients using beta-lactam antibiotics alone and 60 using beta-lactam antibiotics plus fluoroquinolones. Clinical and microbiological responses, spirometry tests, symptom scores, and serum C-reactive protein (CRP) levels were evaluated. RESULTS: Clinical success, lung function, and symptoms were similar in patients with or without fluoroquinolone administration on days 10 and 20. Combination therapy was superior in terms of microbiological outcomes and reduction in serum CRP value. Although equivalent to monotherapy in terms of clinical success, the combination showed superiority in terms of microbiological success and a decrease in CRP. The combination therapy group had a higher microbiological success rate with gram-negative bacteria than the monotherapy group with Pseudomonas aeruginosa (100% vs. 33.3%, respectively) and Acinetobacter baumanii (100% vs. 20%, respectively) (P < 0.05). CONCLUSIONS: Concomitant use of fluoroquinolone and beta-lactam antibiotics for bacterial infections during COPD exacerbations caused by gram-negative bacteria appear to be effective and should be applied in clinical practice.

    Search related documents:
    Co phrase search for related documents
    • accept safety and logistic regression analysis: 1, 2
    • access open and additional effect: 1
    • access open and logistic regression analysis: 1, 2, 3
    • acinetobacter baumannii and active infection: 1, 2, 3, 4
    • acinetobacter baumannii and acute exacerbation: 1, 2, 3
    • acinetobacter baumannii and additional treatment: 1
    • acinetobacter baumannii and logistic regression analysis: 1
    • active infection and adequate sputum sample: 1
    • active infection and logistic regression analysis: 1, 2, 3, 4, 5, 6
    • acute exacerbation and additional effect: 1
    • acute exacerbation and additional treatment: 1
    • acute exacerbation and logistic regression analysis: 1, 2, 3, 4, 5
    • acute worsening and additional treatment: 1
    • acute worsening and logistic regression analysis: 1
    • additional effect and logistic regression analysis: 1, 2, 3, 4
    • additional treatment and logistic regression analysis: 1, 2